A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-524493-42-00

Enrollment

Registered

2026-09-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Fibrosis

Brief summary

Absolute change in forced vital capacity (FVC) measured in mL from baseline to Week 52.

Detailed description

Absolute change in FVC percent predicted (FVCpp) from baseline to Week 52.

Interventions

DRUGDeupirfenidone (LYT-100)

DRUGPirfenidone Zentiva 267 mg compresse rivestite con film

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Absolute change in forced vital capacity (FVC) measured in mL from baseline to Week 52.	—

Secondary

Measure	Time frame
Absolute change in FVC percent predicted (FVCpp) from baseline to Week 52.	—

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 19, 2026